Patients with CLL harboring NOTCH1 mutations do not benefit from therapies incorporating rituximab, likely due to diminished CD20 expression levels in these patients [138, 170]. This evidence concerns the gene NOTCH1 and B-cell chronic lymphocytic leukemia.